3,3'-Diindolylmethane (DIM): A Potential Therapeutic Agent against Cariogenic Streptococcus mutans Biofilm

A Tandem Hydroformylation-Organocatalyzed Friedel-Crafts Reaction for the Synthesis of Diindolylmethanes

Herein, we present an efficient and atom-economic tandem hydroformylation organocatalyzed Friedel-Crafts reaction sequence for the synthesis of diindolylmethanes. Classic syntheses have relied on (Lewis) acid activation of aldehydes, which are often not commercially available and rather sensitive in handling. In contrast, the combination of rhodium-catalyzed hydroformylation and subsequent organocatalytic activation of the in-situ formed aldehydes allows the use of readily available and stable alkenes with various functional groups while avoiding acidic conditions to expand the range of available diindolylmethanes. A broad scope of diindolylmethanes was prepared in yields up to 85 % demonstrates the utility of the presented method.

The Marine Natural Compound Dragmacidin D Selectively Induces Apoptosis in Triple-Negative Breast Cancer Spheroids

Cancer cells grown in 3D spheroid cultures are considered more predictive for clinical efficacy. The marine natural product dragmacidin D induces apoptosis in MDA-MB-231 and MDA-MB-468 triple-negative breast cancer (TNBC) spheroids within 24 h of treatment while showing no cytotoxicity against the same cells grown in monolayers and treated for 72 h. The IC50 for cytotoxicity based on caspase 3/7 cleavage in the spheroid assay was 8 ± 1 µM in MDA-MB-231 cells and 16 ± 0.6 µM in MDA-MB-468 cells at 24 h. No cytotoxicity was seen at all in 2D, even at the highest concentration tested. Thus, the IC50 for cytotoxicity in the MTT assay (2D) in these cells was found to be >75 µM at 72 h. Dragmacidin D exhibited synergy when used in conjunction with paclitaxel, a current treatment for TNBC. Studies into the signaling changes using a reverse-phase protein array showed that treatment with dragmacidin D caused significant decreases in histones. Differential protein expression was used to hypothesize that its potential mechanism of action involves acting as a protein synthesis inhibitor or a ribonucleotide reductase inhibitor. Further testing is necessary to validate this hypothesis. Dragmacidin D also caused a slight decrease in an invasion assay in the MDA-MB-231 cells, although this failed to be statistically significant. Dragmacidin D shows intriguing selectivity for spheroids and has the potential to be a treatment option for triple-negative breast cancer, which merits further research into understanding this activity.